Page last updated: 2024-12-05

etodolac

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Etodolac is a nonsteroidal anti-inflammatory drug (NSAID) that is used to relieve pain and reduce inflammation. It is a derivative of indomethacin and is thought to work by inhibiting the production of prostaglandins, which are chemicals that cause pain and inflammation. Etodolac is available in oral, intravenous, and topical forms. It is commonly used to treat pain from osteoarthritis, rheumatoid arthritis, and other inflammatory conditions. Etodolac is generally well-tolerated, but it can cause side effects such as stomach upset, headache, and dizziness. It can also increase the risk of bleeding in the stomach and intestines. Etodolac is not recommended for people who are allergic to aspirin or other NSAIDs, and it should be used with caution in people with kidney or liver disease. It is also not recommended for pregnant women or women who are breastfeeding. Etodolac is studied for its potential benefits in treating a variety of conditions, including pain from cancer, inflammation caused by Crohn's disease, and chronic pain associated with fibromyalgia. Its efficacy and safety are under continuous evaluation, and ongoing research aims to understand its mechanisms of action and its potential for therapeutic applications.'

Etodolac: A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE). [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

etodolac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3308
CHEMBL ID622
CHEBI ID4909
SCHEMBL ID3903
MeSH IDM0026281

Synonyms (217)

Synonym
AC-4231
MLS001077315
HY-76251
BRD-A74667430-001-05-3
AKOS015838610
MLS000028474 ,
pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro-
2-(1,8-diethyl-4,9-dihydro-3h-pyrano[3,4-b]indol-1-yl)acetic acid
(1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl)acetic acid
1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid
KBIO1_000147
DIVK1C_000147
osteluc
rak-591
edolan
lodine sr
ultradol
lodine
ay-24236
hypen
lodine xl
nsc 282126
ccris 3923
pyrano(3,4-b)indole-1-acetic acid, 1,3,4,9-tetrahydro-1,8-diethyl-
etodolaco [inn-spanish]
pyrano(3,4-b)indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro-(+-)-
ramodar
(+-)-1,8-diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid
etodolacum [inn-latin]
pyrano(3,4-b)indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro-
EU-0100479
SPECTRUM_001244
BSPBIO_003138
PRESTWICK2_000231
PRESTWICK_209
NCGC00016849-01
cas-41340-25-4
SPECTRUM5_001347
pyrano[3, 1,8-diethyl-1,3,4,9-tetrahydro-
ay 24236
ay-24,236
nsc282126
etodolic acid
nsc-282126
1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid
BPBIO1_000333
BSPBIO_000301
LOPAC0_000479
AB00052194
etodolac
C06991
41340-25-4
1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-ylacetic acid
1,3,4,9-tetrahydro-1,8-diethylpyrano(3,4-b)indole-1-acetic acid
(+/-)-1,8-diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid
(1,8-diethyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indol-1-yl)-acetic acid
DB00749
1,8-diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid
lodine (tn)
D00315
etodolac (jp17/usp/inn)
NCGC00089769-04
NCGC00089769-03
smr000058443
KBIO2_006860
KBIO2_004292
KBIO2_001724
KBIOSS_001724
KBIO3_002358
KBIOGR_000680
SPECTRUM4_000410
PRESTWICK1_000231
SPECTRUM2_001387
PRESTWICK0_000231
SPBIO_002222
NINDS_000147
SPECTRUM3_001429
SPBIO_001374
SPECTRUM1501005
PRESTWICK3_000231
IDI1_000147
NCGC00089769-07
NCGC00089769-02
NCGC00089769-05
NCGC00089769-06
NCGC00015399-04
HMS2092O20
E 0516
NCGC00015399-11
napilac
ay-24-236
(rs)-etodolic acid
tedolan
eccoxolac
nih-9918
lodin xl
flancox
zedolac
CHEMBL622 ,
CHEBI:4909 ,
etodolaco
etodolacum
HMS500H09
FT-0668424
FT-0668425
HMS1568P03
HMS1921B09
bdbm50016799
2-(1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl)acetic acid
HMS3261O20
HMS3259P10
HMS2095P03
tox21_202218
NCGC00259767-01
etodlic acid
E0858
pharmakon1600-01501005
nsc-757821
nsc757821
dtxsid9020615 ,
dtxcid30615
tox21_110644
HMS2231D04
CCG-39005
NCGC00015399-03
NCGC00015399-07
NCGC00015399-13
NCGC00015399-12
NCGC00015399-09
NCGC00015399-06
NCGC00015399-08
NCGC00015399-05
2m36281008 ,
etodolac [usan:usp:inn:ban]
unii-2m36281008
FT-0607046
NCGC00015399-15
LP00479
CS-0832
HMS3374G09
gtpl7185
2-{1,8-diethyl-1h,3h,4h,9h-pyrano[3,4-b]indol-1-yl}acetic acid
etodolac [green book]
etodolac [usp monograph]
etodolac [mart.]
etodolac [jan]
(+/-)-etodolac
pyrano(3,4-b)indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro-(+/-)-
etodolac [who-dd]
etodolac [ep monograph]
etodolac [mi]
etodolac [orange book]
etodolac [usan]
etodolac [vandf]
1,8-diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indol-1-acetic acid
etodolac [usp-rs]
etodolac [inn]
87226-38-8
MLS006011566
NC00718
SCHEMBL3903
tox21_110644_1
NCGC00015399-16
tox21_500479
NCGC00261164-01
etodolac o
F2173-0681
Q-201099
pyrano(3,4,b)indole-1-acetic acid, 1,3,4,9-tetrahydro-1,8-diethyl-
1,8-diethyl-1,3,4,9-tetrahydropyranol[3,4-b]indole-1-acetic acid
(rs)-2-(1,8-diethyl-4,9-dihydro-3h-pyrano[3,4-b]indol-1-yl)acetic acid
rac-etodolac
OPERA_ID_1774
AB00052194_17
mfcd00133313
sr-01000000100
SR-01000000100-2
etodolac, united states pharmacopeia (usp) reference standard
etodolac, european pharmacopoeia (ep) reference standard
etodolac for peak identification, european pharmacopoeia (ep) reference standard
SR-01000000100-7
SR-01000000100-4
SBI-0050463.P003
HMS3712P03
1,8-diethyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indole-1-acetic acid
Z1521549186
etodolac,(s)
Q2465218
BCP28411
ay 24,236; ay 24236;ay-24,236; ay-24236; ay24,236; ay24236
BRD-A74667430-001-15-2
SDCCGSBI-0050463.P004
NCGC00015399-26
2-(1,8-diethyl-4,9-dihydro-3h-pyrano[3,4-b]indol-1-yl)acetic acid.
etogesic
etodolac assay standard
etodolac for peak identification
etodolac- bio-x
BR164431
EN300-119494
SY057989
etodolsaure
(1,8-diethyl-1,3,4,9-tetrahydro-pyrano(3,4-b)indol-1-yl)-acetic acid
etodolaco (inn-spanish)
1,8-diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indol-1-ylacetic acid
m01ab08
(1,8-diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indol-1-yl)acetic acid
etodolacum (inn-latin)
etodolac (usan:usp:inn:ban)
etodolacer
etodolac (usp monograph)
etogesic sterile injectable solution
2-((1rs)-1,8-diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indol-1-yl)acetic acid
etodolac (ep monograph)
etodolac (usp-rs)
etodolac (mart.)
etogesic tablets

Research Excerpts

Overview

Etodolac is a selective cyclo-oxygenase-2 (COX-2) inhibitor, with evidence of efficacy in osteoarthritis and rheumatoid arthritis. It is a nonsteroidal anti-inflammatory drug which has been demonstrated to protect liver against fibrosis.

ExcerptReferenceRelevance
"Etodolac is a selective cycloxygenase- 2 (COX -2) inhibitor non-steroidal anti-inflammatory drug used as an analgesic and anti-inflammatory in musculoskeletal diseases."( Acute Liver Failure Due to Etodolac, a Selective Cycloxygenase- 2 (COX -2) Inhibitor Non-Steroidal Anti-Inflammatory Drug Established by RUCAM-Based Causality Assessment.
Chawla, YK; Dhiman, RK; Duseja, A; Kumar, P; Rathi, S; Singh, V; Taneja, S,
)
1.15
"Etodolac is a non-steroidal anti-inflammatory drug having an elimination half-life of 7 h; oral doses are given every 6-8 h. "( Sucrose stearate-enriched lipid matrix tablets of etodolac: modulation of drug release, diffusional modeling and structure elucidation studies.
Abd-Elbary, A; Alaa-Eldin, AA; Tadros, MI, 2013
)
2.09
"Etodolac is a cyclooxygenase (COX)-2 inhibitor that belongs to the class of nonsteroidal anti-inflammatory drugs (NSAIDs)."( Etodolac activates and desensitizes transient receptor potential ankyrin 1.
Dai, Y; Kogure, Y; Noguchi, K; Wang, S; Yamamoto, S; Zhang, W, 2013
)
2.55
"Etodolac is a nonsteroidal anti-inflammatory drug which has been demonstrated to protect liver against fibrosis."( Impact of N-acetylcysteine and etodolac treatment on systolic and diastolic function in a rat model of myocardial steatosis induced by high-fat-diet.
Akkoc, H; Akkus, M; Kelle, I; Topal, AE; Topal, D; Yilmaz, S, 2014
)
1.41
"Etodolac is a non-steroidal anti-inflammatory drug with preferential inhibition of cyclooxigenase-2 and is widely used in the management of pain in patients with inflammatory arthritis. "( Enantioselective analysis of etodolac in human plasma by LC-MS/MS: Application to clinical pharmacokinetics.
da Silva, LM; de Miranda Silva, C; Donadi, EA; Lanchote, VL; Rocha, A; Tozatto, E, 2016
)
2.17
"Etodolac is a selective cyclo-oxygenase-2 (COX-2) inhibitor, with evidence of efficacy in osteoarthritis and rheumatoid arthritis. "( Single dose oral etodolac for acute postoperative pain in adults.
Derry, S; McQuay, HJ; Moore, RA; Tirunagari, SK, 2009
)
2.14
"Etodolac (E), is a non-narcotic analgesic and antiinflammatory drug. "( Dextran-etodolac conjugates: synthesis, in vitro and in vivo evaluation.
Chaturvedi, SC; Trivedi, P; Vyas, S,
)
2.01
"Etodolac (ET) is a nonsteroidal anti-inflammatory drug with proved potential antitumor and uric acid lowering effects. "( Polymeric surfactant based etodolac chewable tablets: formulation and in vivo evaluation.
El-Nabarawi, M; El-Setouhy, DA; Fadlalla, MA; Ibrahim, MM, 2010
)
2.1
"Etodolac is a generic nonsteroidal anti-inflammatory drug (NSAID). "( Risks of clinically significant upper gastrointestinal events with etodolac and naproxen: a historical cohort analysis.
Cryer, B; Cung, A; Kazi, S; Kelly, KC; Little, BB; Roberts, KW; Sarosi, GA; Smith, HJ; Weideman, RA, 2004
)
2
"Etodolac is a generic COX-2 selective inhibitor that reduces CSUGI events compared with the nonselective NSAID naproxen. "( Risks of clinically significant upper gastrointestinal events with etodolac and naproxen: a historical cohort analysis.
Cryer, B; Cung, A; Kazi, S; Kelly, KC; Little, BB; Roberts, KW; Sarosi, GA; Smith, HJ; Weideman, RA, 2004
)
2
"R-etodolac (SDX-101) is an isoform of the non-steroidal anti-inflammatory drug, etodolac, and is currently being tested in phase II clinical trials for the treatment of refractory B-cell chronic lymphocytic leukemia (B-CLL). "( Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells.
Cebula, B; Linke, A; Robak, P; Robak, T; Smolewski, P, 2006
)
1.37
"R-etodolac is a novel pro-apoptotic agent with potential antitumor activity against B-cell chronic lymphocytic leukemia (B-CLL). "( Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia.
Engert, A; Jensen, M; Kimby, E; Knauf, W; Oliff, IA; Osterborg, A; Poynton, C; Rummel, MJ; Weissinger, F, 2008
)
1.33
"Etodolac (Ultradol) is a new tetrahydropyrano-indole derivative which has shown pronounced analgesic and antiinflammatory properties. "( Comparative effects of etodolac, indomethacin, and benoxaprofen on icosanoid biosynthesis.
Borgeat, P; Salari, H; Saura, C; Sirois, P, 1984
)
2.02
"Etodolac is a new pyranocarboxylic acid nonsteroidal anti-inflammatory agent with a unique chemical structure indicated for use in patients with painful musculoskeletal disorders and rheumatoid disease. "( Fulminant hepatic failure associated with etodolac use.
Baker, PB; Kirkpatrick, RB; Levine, EJ; Mabee, CL; Mabee, SW, 1995
)
2
"Etodolac is a chiral nonsteroidal anti-inflammatory drug (NSAID) that is marked as the racemate. "( Etodolac clinical pharmacokinetics.
Brocks, DR; Jamali, F, 1994
)
3.17
"Etodolac is a relative selective inhibitor of COX-2, while ibuprofen has a higher potency against COX-1 than COX-2."( A comparison of the effects of etodolac and ibuprofen on renal haemodynamics, tubular function, renin, vasopressin and urinary excretion of albumin and alpha-glutathione-S-transferase in healthy subjects: a placebo-controlled cross-over study.
Bech, JN; Pedersen, EB; Svendsen, KB; Sørensen, TB, 2000
)
1.31
"Etodolac is a new nonsteroidal anti-inflammatory drug (NSAID). "( Clinical response to etodolac in the management of pain.
Mizraji, M, 1990
)
2.04
"Etodolac is a nonsteroidal anti-inflammatory drug (NSAID) effective in the treatment of rheumatoid arthritis, osteoarthritis and ankylosing spondylitis, and in the alleviation of postoperative pain. "( Etodolac. A reappraisal of its pharmacology and therapeutic use in rheumatic diseases and pain states.
Balfour, JA; Buckley, MM, 1991
)
3.17
"Etodolac is a new NSAID which is an effective inhibitor of PGE2 synthesis."( Etodolac preserves cartilage-specific phenotype in human chondrocytes: effects on type II collagen synthesis and associated mRNA levels.
Chang, JY; Elwell, JM; Goldring, MB; Sohbat, E, 1990
)
2.44
"Etodolac is a new nonsteroidal anti-inflammatory drug (NSAID) with potent analgesic and antiarthritic properties. "( An overview of the efficacy of etodolac in arthritic disorders.
Bacon, PA, 1990
)
2.01
"Etodolac is a new nonsteroidal anti-inflammatory drug (NSAID) that has shown a favorable safety profile in clinical trials in osteoarthritis (OA) and rheumatoid arthritis (RA). "( Global safety of etodolac: reports from worldwide postmarketing surveillance studies.
Serni, U, 1990
)
2.06
"Etodolac is a new non-steroidal agent (NSAID) with anti-inflammatory and analgesic activity. "( Etodolac. A preliminary review of its pharmacodynamic activity and therapeutic use.
Brogden, RN; Lynch, S, 1986
)
3.16
"Etodolac is a structurally novel compound exhibiting potent analgesic and anti-inflammatory activity in laboratory animals and man, with excellent G. "( Etodolac: effect on prostaglandin concentrations in gastric mucosa of rats.
Dvornik, D; Lee, D, 1985
)
3.15

Effects

Etodolac (Lodine) has been marketed in the United States since 1991 for managing pain and for acute and longterm treatment of the signs and symptoms of osteoarthritis (OA) The drug has been shown to have a favorable safety profile in short-term and long-term studies.

ExcerptReferenceRelevance
"Etodolac (Lodine) has been marketed in the United States since 1991 for managing pain and for acute and longterm treatment of the signs and symptoms of osteoarthritis (OA). "( Etodolac (Lodine) in the treatment of osteoarthritis: recent studies.
Constantine, G; Schnitzer, TJ, 1997
)
3.18
"Etodolac has been shown to have a favorable safety profile in short-term and long-term studies in both osteoarthritis (OA) and rheumatoid arthritis (RA). "( Endoscopic evaluation of etodolac and naproxen, and their relative effects on gastric and duodenal prostaglandins.
Russell, RI, 1990
)
2.03
"Etodolac has also been shown to be very well tolerated."( A review of the antiarthritic efficacy and safety of etodolac.
Zvaifler, N, 1989
)
1.25
"Etodolac has previously been reported to have an excellent safety profile. "( A global safety evaluation of etodolac.
Karbowski, A, 1989
)
2.01
"Etodolac has been shown to be clinically effective with a low incidence of adverse effects."( Therapeutic choices for rheumatic disorders.
Hughes, G, 1988
)
1

Actions

ExcerptReferenceRelevance
"Etodolac did not increase the inhibitory effect of 5-FU on cell proliferation."( Combined treatment with selective cyclooxygenase-2 inhibitor and fluorinated pyrimidines for liver metastasis of colon cancer.
Hirakawa, K; Matsunaga, N; Nishiguchi, Y; Nishino, H; Ohira, M; Seki, S; Tachimori, A; Yamada, N, 2004
)
1.04

Treatment

The etodolac SR treatment group showed fewer incidents of adverse event. One etodlac-treated patient withdrew from treatment because of a rash. Three etodilac- treated patients and two naproxen-treated patients reported minor upper gastrointestinal discomfort.

ExcerptReferenceRelevance
"The etodolac SR treatment group showed fewer incidents of adverse event."( Double-blind, randomised, comparative trial of etodolac SR versus diclofenac in the treatment of osteoarthritis of the knee.
Hsu, PN; Liang, TH, 2003
)
1.06
"One etodolac-treated patient withdrew from treatment because of a rash; three etodolac-treated patients and two naproxen-treated patients reported minor upper gastrointestinal discomfort."( Double-blind comparison of etodolac and naproxen in the treatment of rheumatoid arthritis.
de Queiros, MF,
)
0.91
"iii) Treatment with etodolac alone."( Inhibitory effects of the cyclooxygenase-2 inhibitor, etodolac, on colitis-associated tumorigenesis in p53-deficient mice treated with dextran sulfate sodium.
Abe, A; Fujii, S; Fujimori, T; Fukui, H; Hiraishi, H; Ichikawa, K; Imura, J; Kono, T; Mukawa, K; Ono, Y; Sekikawa, A; Shinoda, M; Tominaga, K; Tomita, S; Yoshitake, N, 2008
)
0.91

Toxicity

Drug-related adverse events were noted in 8 patients with 1,000 mg paracetamol. Adverse reactions, mostly regarding the G-I tract, were significantly more frequent in the tenoxicam group than the etodolac group.

ExcerptReferenceRelevance
" There was no significant difference between treatment groups in the number of patient withdrawals due to adverse reactions or in the number of patients reporting side effects."( Safety and efficacy of etodolac compared with piroxicam in patients with degenerative joint disease of the knee.
Bulstra, S; Dick, WC; Feenstra, RM; Schardijn, GH,
)
0.44
" The elderly appear to be no more at risk of experiencing adverse effects than the general population."( An updated safety profile of etodolac in several thousand patients.
Schattenkirchner, M, 1990
)
0.57
" Only 9% of all the patients treated withdrew from these studies because of adverse effects."( Global safety of etodolac: reports from worldwide postmarketing surveillance studies.
Serni, U, 1990
)
0.62
" A total of 1276 adverse reactions (AR) were reported during the study, and fewer than half of these were related to study treatment."( Large-scale open trials with etodolac (Lodine) in France: an assessment of safety.
Benhamou, CL, 1990
)
0.57
" Adverse reactions, mostly regarding the G-I tract, were significantly more frequent in the tenoxicam group than in the etodolac group: 23."( Double-blind comparison of the efficacy and safety of etodolac SR 600 mg u.i.d. and of tenoxicam 20 mg u.i.d. in elderly patients with osteoarthritis of the hip and of the knee.
Bogliolo, A; Perpignano, G; Puccetti, L, 1994
)
0.75
" Of 273 elderly patients treated with at least 600 mg daily, only 12% withdrew because of adverse events, a rate similar to that in the younger age-group."( Safety profile of etodolac in the elderly population.
Bacon, PA, 1994
)
0.62
" The incidence of adverse events caused by either drug was the same."( A comparative study of the efficacy and toxicity of etodolac and naproxen in the treatment of osteoarthritis.
Bird, H; Chikanza, IC; Clarke, B; Grahame, R; Hopkins, R; MacFarlane, DG,
)
0.38
" Withdrawals due to adverse reactions were low, occurring in only 5% (26/539) of all patients."( The safety profile of sustained-release etodolac.
Schattenkirchner, M, 1993
)
0.55
" There were no significant between-group differences in the numbers of patients who had an adverse experience, a serious adverse experience, or an adverse experience leading to study discontinuation; there were also no significant between-group differences in the distribution of adverse experiences."( Efficacy and safety of etodolac and naproxen in patients with osteoarthritis of the knee: a double-blind, placebo-controlled study.
Ballard, I; Constantine, G; Dore, R; McDonald, P,
)
0.44
" No significant differences occurred in the incidence of any specific adverse event."( Comparison of the efficacy and safety of etodolac and piroxicam in patients with rheumatoid arthritis. Etodolac Study 326 Rheumatoid Arthritis Investigators Group.
Lightfoot, R, 1997
)
0.56
"To summarize current evidence that three new additions to nonsteroidal anti-inflammatory drugs (NSAIDs) offer comparable efficacy with fewer adverse effects than established NSAIDs."( Newer, safer nonsteroidal anti-inflammatory drugs. Rational NSAID selection for arthritis.
Bensen, W; Zizzo, A, 1998
)
0.3
"Using misoprostol in conjunction with traditional NSAIDs reduces gastric and renal adverse effects."( Newer, safer nonsteroidal anti-inflammatory drugs. Rational NSAID selection for arthritis.
Bensen, W; Zizzo, A, 1998
)
0.3
" However, as demonstrated by oxaprozin, considered to be one of the least safe NSAIDs but one of the leading drugs on the US market, success may not be dependent on safety."( Safety profiles of leading nonsteroidal anti-inflammatory drugs.
Rothstein, R, 1998
)
0.3
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
"The identification of a safe and reliable alternative for patients with non-steroidal anti-inflammatory drug (NSAID)-induced urticaria/angioedema is a frequent problem for dermatologists and other practitioners."( Safety of selective cyclooxygenase-2 inhibitors and a basic non-steroidal anti-inflammatory drug (NSAID) in Japanese patients with NSAID-induced urticaria and/or angioedema: Comparison of meloxicam, etodolac and tiaramide.
Chiba, Y; Ikezawa, Z; Inomata, N; Kambara, T; Onoda, M; Osuna, H; Takeshita, Y; Yamaguchi, J, 2007
)
0.53
"To evaluate adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs."( Evaluation of adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs.
Basílio, AC; Brandão, CV; Luna, SP; Machado, LP; Moutinho, FQ; Steagall, PV; Takahira, RK, 2007
)
0.8
"Carprofen induced the lowest frequency of gastrointestinal adverse effects, followed by meloxicam."( Evaluation of adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs.
Basílio, AC; Brandão, CV; Luna, SP; Machado, LP; Moutinho, FQ; Steagall, PV; Takahira, RK, 2007
)
0.57
" The adverse events reported were few and no serious adverse events were reported."( A multicentric, randomized, comparative clinical trial to evaluate the efficacy and safety of S-etodolac in the treatment of osteoarthritis in Indian patients.
Basu, I; Hardikar, M; Karne, N; Maria, A; Panse, J; Sancheti, P; Singh, S, 2010
)
0.58
" Both treatments were well tolerated and safe in patients with OA flare-up."( Efficacy and safety of etodolac-paracetamol fixed dose combination in patients with knee osteoarthritis flare-up: a randomized, double-blind comparative evaluation.
Ambade, R; Bartakke, G; Chandanwale, A; Chandurkar, N; Pareek, A, 2010
)
0.67
" Drug-related adverse events were noted in 8 patients with 1,000 mg paracetamol, in 9 patients with 400 mg etodolac and in 9 patients for 800 mg etodolac during the study."( Efficacy and safety of 400 and 800 mg etodolac vs. 1,000 mg paracetamol in acute treatment of migraine: a randomized, double-blind, crossover, multicenter, phase III clinical trial.
Baykan, B; Ertaş, M; Özge, A; Öztürk, V; Sirin, H, 2013
)
0.87
"Our study showed that etodolac is a safe and effective alternative in acute migraine treatment and showed comparable efficacy to paracetamol 1,000 mg."( Efficacy and safety of 400 and 800 mg etodolac vs. 1,000 mg paracetamol in acute treatment of migraine: a randomized, double-blind, crossover, multicenter, phase III clinical trial.
Baykan, B; Ertaş, M; Özge, A; Öztürk, V; Sirin, H, 2013
)
0.98
"Many adverse drug reactions are caused by the cytochrome P450 (CYP)-dependent activation of drugs into reactive metabolites."( Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Jones, LH; Nadanaciva, S; Rana, P; Will, Y, 2016
)
0.43
" Reports of gastrointestinal adverse effects with traditional NSAIDs and cardiovascular adverse effects associated with selective cyclooxygenase-2 (COX-2) inhibitors have prompted the hunt for a better NSAID with no or minimal adverse effects."( Comparison of Clinical Effectiveness and Safety of Newer Nonsteroidal Anti-inflammatory Drugs in Patients of Osteoarthritis of Knee Joint: A Randomized, Prospective, Open-label Parallel-group Study.
Garg, Y; Gore, R; Kumar, A; Singh, J; Sohal, HS,
)
0.13

Pharmacokinetics

The study was a single-center, open-label, single-dose pharmacokinetic study of etodolac in pediatric and adolescent patients with stable juvenile rheumatoid arthritis (JRA) The elimination half-life of etdolac is between 6 and 8 hours in plasma, and is similar for both enantiomers.

ExcerptReferenceRelevance
"The present study describes the pharmacokinetic behaviour of a new dosage form of etodolac not available in the Spanish market: suppositories."( Pharmacokinetic study of etodolac after rectal administration; "in vitro" release kinetics.
Barcia, E; Cadorniga, R; Fabregas, JL; Guitierrez, JA; Herrero, R; Martinez-Tobed, A; Molina, IT, 1991
)
0.81
" No evidence of a pharmacokinetic interaction between the enantiomers was observed."( The pharmacokinetics of etodolac enantiomers in the rat. Lack of pharmacokinetic interaction between enantiomers.
Brocks, DR; Jamali, F,
)
0.44
" The mean half-life (t1/2) was 6 to 7 hours."( Profile of etodolac: pharmacokinetic evaluation in special populations.
Brater, DC; Lasseter, KC, 1989
)
0.67
" No differences in the half-life of etodolac elimination were noted."( The pharmacokinetics of etodolac in serum and synovial fluid of patients with arthritis.
Furst, D; Furst, J; Hicks, DR; Kraml, M; McKean, M; Panagides, J, 1988
)
0.86
"An HPLC assay suitable for pharmacokinetic analysis of enantiomers of etodolac [(+/-)-1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b] indole-1-acetic acid] was developed."( Application of a stereospecific high-performance liquid chromatography assay to a pharmacokinetic study of etodolac enantiomers in humans.
Eradiri, O; Jamali, F; Lemko, C; Mehvar, R, 1988
)
0.72
" To investigate the effect of disease states or concomitant drug administration on a patient's response to etodolac, additional pharmacokinetic studies were carried out in special populations."( Pharmacokinetic profile of etodolac in special populations.
Benet, LZ, 1994
)
0.8
" The elimination half-life of etodolac is between 6 and 8 hours in plasma, and is similar for both enantiomers."( Etodolac clinical pharmacokinetics.
Brocks, DR; Jamali, F, 1994
)
2.02
"The goal of this study was to look for correlations between the severity of chronic inflammatory joint disease and pharmacokinetic parameters of nonsteroidal antiinflammatory drugs."( Influence of severity of chronic inflammatory joint disease on the pharmacokinetics of indomethacin and etodolac.
Goasguen, J; Guggenbuhl, P; Jacquelinet, C; Lapicque, F; Le Dantec, P; Netter, P; Pawlotsky, Y; Perdriger, A; Veillard, E, 1996
)
0.51
" The plasma concentrations of the drug in bile duct-linked rats approximately agreed with the simulation curve by the model, with the peak concentration 6-7 h after dosing."( Pharmacokinetic analysis of enterohepatic circulation of etodolac and effect of hepatic and renal injury on the pharmacokinetics.
Iwaki, M; Kitagawa, T; Ogiso, T; Tanino, T, 1997
)
0.54
"The objective of this double-blind, randomized, parallel-group study was to evaluate the pharmacokinetics of etodolac and the pharmacodynamic response of pain in patients following oral surgery who had received 200 or 400 mg of etodolac immediate release (IR), 400 or 1200 mg of etodolac extended release (ER), or a placebo."( Pharmacokinetic and pharmacodynamic action of etodolac in patients after oral surgery.
Appel, A; Boni, J; Cooper, S; Korth-Bradley, J; McGoldrick, K, 1999
)
0.77
"This was a single-center, open-label, single-dose pharmacokinetic study of etodolac in pediatric and adolescent patients with stable juvenile rheumatoid arthritis (JRA)."( Pharmacokinetics of etodolac in patients with stable juvenile rheumatoid arthritis.
Boni, JP; Korth-Bradley, JM; Martin, P; Rennebohm, R; Richards, LS; Simcoe, DK; Walson, PD, 1999
)
0.86
"To study whether etodolac enantiomers have pharmacokinetic difference after oral administration."( Pharmacokinetic difference between S-(+)- and R-(-)-etodolac in rats.
Duan, GL; Lai, SG; Li, D; Shi, JM; Xu, CJ, 2004
)
0.91
" The main pharmacokinetic parameters of S-(+)- and R-(-)-etodolac were as follows: t1/2(lambdaz) 18+/-4 h vs 19."( Pharmacokinetic difference between S-(+)- and R-(-)-etodolac in rats.
Duan, GL; Lai, SG; Li, D; Shi, JM; Xu, CJ, 2004
)
0.82
"There is pharmacokinetic difference between S-(+)- and R-(-)- etodolac enantiomers in rats after oral administration."( Pharmacokinetic difference between S-(+)- and R-(-)-etodolac in rats.
Duan, GL; Lai, SG; Li, D; Shi, JM; Xu, CJ, 2004
)
0.81
" The development of NSAIDs having safer therapeutic profile depends on the better understanding of their mechanisms, physicochemical and pharmacokinetic properties."( Self-organizing molecular field analysis of NSAIDs: assessment of pharmacokinetic and physicochemical properties using 3D-QSPkR approach.
Kumar, M; Sinha, VR; Thareja, S, 2012
)
0.38
" The validated method was successfully applied to the determination of etodolac enantiomers in tablets and to a comparative pharmacokinetic study of the two enantiomers after the administration of 300 mg single oral dose etodolac racemate tablets to twelve healthy volunteers."( Enantioselective HPLC-DAD method for the determination of etodolac enantiomers in tablets, human plasma and application to comparative pharmacokinetic study of both enantiomers after a single oral dose to twelve healthy volunteers.
Elmongy, HA; Hewala, II; Moneeb, MS; Wahbi, AA, 2014
)
0.88
" The pharmacokinetic parameters were calculated from the plasma samples and data form the reference and test drugs were represented as follows; Area under plasma concentration-time curve (AUCt) (78."( Quantification of Etodolac in Human Plasma for Pharmacokinetics and Bioequivalence Studies in 27 Korean Subjects.
Chun, MY; Kang, JS; Kim, HJ; Kim, SH; Kim, SM; Lee, KH; Song, ID; Zhao, DX, 2017
)
0.79
"Thus, the new testified method was successfully applied for the pharmacokinetic and bioequivalence studies for two etodolac formulations."( Quantification of Etodolac in Human Plasma for Pharmacokinetics and Bioequivalence Studies in 27 Korean Subjects.
Chun, MY; Kang, JS; Kim, HJ; Kim, SH; Kim, SM; Lee, KH; Song, ID; Zhao, DX, 2017
)
1
" The pharmacokinetic study in human volunteers showed that the selected etodolac-loaded cubosomes enhanced the bioavailability of etodolac as compared to the oral capsules (266."( Etodolac transdermal cubosomes for the treatment of rheumatoid arthritis: ex vivo permeation and in vivo pharmacokinetic studies.
Kamel, AO; Mahmoud, AA; Salah, S, 2017
)
2.13
" post-surgery celecoxib/etoricoxib/etodolac pharmacokinetic (PK) profiles."( Selective COX-2 inhibitors after bariatric surgery: Celecoxib, etoricoxib and etodolac post-bariatric solubility/dissolution and pharmacokinetics.
Cvijić, S; Dahan, A; Dukhno, O; Partook-Maccabi, M; Porat, D; Vainer, E, 2023
)
1.42

Compound-Compound Interactions

The beta-blocker propranolol, combined with the COX-2 inhibitor etodolac has been shown to reduce metastatic spread and increase survival rates following surgery for primary tumor excision in rodents.

ExcerptReferenceRelevance
" The present study investigated the efficacy of NTG combined with the nonsteroidal anti-inflammatory drug etodolac for the treatment of CPP."( Efficacy of transdermal nitroglycerin combined with etodolac for the treatment of chronic post-thoracotomy pain: an open-label prospective clinical trial.
Eidelman, LA; Glantz, L; Godovic, G; Kramer, M; Lekar, M, 2004
)
0.79
" The aim of this study was to evaluate the cytotoxicity of SDX-101 combined with agents proven to be effective as first-line treatment of B-CLL: the purine nucleoside analogs, fludarabine (FA) and cladribine (2-CdA), and the monoclonal antibodies, anti-CD52 (alemtuzumab; ALT) and anti-CD20 (rituximab; RIT)."( Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells.
Cebula, B; Linke, A; Robak, P; Robak, T; Smolewski, P, 2006
)
0.65
"Pharmacologic modulation of the perioperative physiologic stress response, using the beta-blocker propranolol, combined with the COX-2 inhibitor etodolac, has been shown to reduce metastatic spread and increase survival rates following surgery for primary tumor excision in rodents."( Effect of beta blocker combined with COX-2 inhibitor on colonic anastomosis in rats.
Barshack, I; Ben-Eliyahu, S; Benish, M; Benjamin, B; Hazut, O; Hoffman, A; Shaashua, L; Zmora, N; Zmora, O, 2010
)
0.56
"2 mg/kg/day) combined with etodolac (12."( Effect of beta blocker combined with COX-2 inhibitor on colonic anastomosis in rats.
Barshack, I; Ben-Eliyahu, S; Benish, M; Benjamin, B; Hazut, O; Hoffman, A; Shaashua, L; Zmora, N; Zmora, O, 2010
)
0.66
" Drug-drug multicomponent adducts could help in combination of drugs at supramolecular level."( Fast dissolving drug-drug eutectics with improved compressibility and synergistic effects.
Chavan, R; Naidu, VGM; Shastri, NR; Thipparaboina, R; Thumuri, D, 2017
)
0.46

Bioavailability

The objective of this study was to prepare a self-emulsifying drug delivery system (SEDDS) for oral bioavailability enhancement of a poorly water-soluble drug, etodolac. The effects of formulation, particle size, coadministration of food, antacids, or antiulcer agents on the bioavailability of etodlac have been evaluated in dogs.

ExcerptReferenceRelevance
"The effects of formulation, particle size, coadministration of food, antacids, or antiulcer agents on the bioavailability of etodolac (ULTRADOL, 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid), a novel non-steroidal anti-inflammatory agent, have been evaluated in dogs and man."( Bioavailability studies with etodolac in dogs and man.
Cosyns, L; Dvornik, D; Hicks, DR; Kraml, M; Mullane, JF; Simon, J,
)
0.63
" This results in an increase in the rate of absorption of the active compound and, consequently, in an earlier onset of analgesic action."( Piroxicam-beta-cyclodextrin in the treatment of acute pain of rheumatic disease.
Franchimont, P; Reginster, JY, 1993
)
0.29
"The dissolution and bioavailability of etodolac from capsules exposed to high relative humidity and temperature were compared to those from capsules stored at room temperature (RT)."( The dissolution and bioavailability of etodolac from capsules exposed to conditions of high relative humidity and temperatures.
Dey, M; Enever, R; Kraml, M; Prue, DG; Smith, D; Weierstall, R, 1993
)
0.82
" Finally, with formulation A (tablets) as a reference, the relative bioavailability was established, on the basis of the ratio (B:A) of AUC0t and AUC 9 infinity, within the range 100 +/- 20%."( Bioavailability and bioequivalence of two formulations of etodolac (tablets and suppositories).
Cadorniga, R; Fábregas, JL; Gutiérrez, JA; Herrero, R; Iglesias, JM; Martinez-Tobed, A; Molina-Martinez, IT, 1993
)
0.53
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
"To examine the influence of absorption rate on etodolac bioequivalence as measured by total [(R,S)-] and (S)-etodolac."( Chiral bioequivalence: effect of absorption rate on racemic etodolac.
Benet, LZ; Boni, JR; Chiang, ST; Hicks, DR; Korth-Bradley, JM; Richards, LS, 2000
)
0.81
" Bioavailability was approximately 77."( Pharmacokinetics of etodolac in the horse following oral and intravenous administration.
Blikslager, AT; Campbell, NB; Davis, JL; Gayle, J; Morton, AJ; Papich, MG, 2007
)
0.66
"The objective of this study was to prepare a self-emulsifying drug delivery system (SEDDS) for oral bioavailability enhancement of a poorly water-soluble drug, etodolac."( Enhanced oral bioavailability of etodolac by self-emulsifying systems: in-vitro and in-vivo evaluation.
Barakat, NS, 2010
)
0.84
"An optimized formulation of SEDDS (composed of 20% etodolac, 30% oil Labrafac WL1349, 10% Lauroglycol 90 and 40% Labrasol) was selected for bioavailability assessment in rabbits."( Enhanced oral bioavailability of etodolac by self-emulsifying systems: in-vitro and in-vivo evaluation.
Barakat, NS, 2010
)
0.89
" When compared to the commercial immediate-release Napilac® capsules, the optimum CPOP tablets (F4-34) provided enhanced bioavailability and extended duration of effective etodolac plasma concentration with minimum expected potential for side effects in healthy volunteers."( Development and in vitro/in vivo evaluation of etodolac controlled porosity osmotic pump tablets.
Abd-Elbary, A; Alaa-Eldin, AA; Tadros, MI, 2011
)
0.82
"Poor transdermal penetration of active pharmaceutical ingredients (APIs) impairs both bioavailability and therapeutic benefits and is a major challenge in the development of transdermal drug delivery systems."( Lidocaine self-sacrificially improves the skin permeation of the acidic and poorly water-soluble drug etodolac via its transformation into an ionic liquid.
Hamamoto, H; Ishida, T; Miwa, Y, 2016
)
0.65
" The pharmacokinetic study in human volunteers showed that the selected etodolac-loaded cubosomes enhanced the bioavailability of etodolac as compared to the oral capsules (266."( Etodolac transdermal cubosomes for the treatment of rheumatoid arthritis: ex vivo permeation and in vivo pharmacokinetic studies.
Kamel, AO; Mahmoud, AA; Salah, S, 2017
)
2.13
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Assessment of bioavailability was based on a pharmacokinetic study on rabbits and pharmacodynamics evaluation on rats, respectively."( Enhanced Oral Bioavailability of Etodolac by the Liquisolid Compact Technique: Optimisation, In-Vitro and In-Vivo Evaluation.
Pathak, BK; Raghav, M; Shah, PJ; Thakkar, AR; Vyas, BA, 2021
)
0.9
"The results indicated the liquisolid compact technique to be a promising strategy to enhance the bioavailability of Etodolac."( Enhanced Oral Bioavailability of Etodolac by the Liquisolid Compact Technique: Optimisation, In-Vitro and In-Vivo Evaluation.
Pathak, BK; Raghav, M; Shah, PJ; Thakkar, AR; Vyas, BA, 2021
)
1.11

Dosage Studied

The study describes the pharmacokinetic behaviour of a new dosage form of etodolac not available in the Spanish market: suppositories. A single 1200 mg dose of etdolac ER given once daily was shown to provide substantial efficacy for 13 hours after dose.

ExcerptRelevanceReference
"The present study describes the pharmacokinetic behaviour of a new dosage form of etodolac not available in the Spanish market: suppositories."( Pharmacokinetic study of etodolac after rectal administration; "in vitro" release kinetics.
Barcia, E; Cadorniga, R; Fabregas, JL; Guitierrez, JA; Herrero, R; Martinez-Tobed, A; Molina, IT, 1991
)
0.81
" An open clinical trial performed by 974 rheumatologists enabled an evaluation of efficacy, safety and therapeutic benefit of etodolac (Lodine 200) on 4,947 patients with rheumatoid arthritis, ankylosing spondylitis and osteoarthritis of the lower limbs; the initial dosage was 600 mg/d (for 2 weeks), then 400 to 600 mg/d (for 2 to 4 weeks, according to the indication)."( [Efficacy, tolerability and therapeutic benefit of etodolac (Lodine 200) in rheumatologic practice].
Benhamou, CL; Dropsy, R; Feldmann, JL,
)
0.59
" These findings suggest that no alteration of etodolac dosage would be necessary in these high-risk groups."( Profile of etodolac: pharmacokinetic evaluation in special populations.
Brater, DC; Lasseter, KC, 1989
)
0.93
"Twenty subjects (10 with normal renal function and 10 with moderate renal insufficiency) participated in an 8-day study to assess the effects of acute and chronic etodolac dosing on renal function."( Effect of etodolac in patients with moderate renal impairment compared with normal subjects.
Anderson, SA; Brater, DC; Brown-Cartwright, D; Chen, A; Jacob, GB; Toto, RD, 1985
)
0.87
" A dose-response relationship was found for the three doses of etodolac, which was significant for summed pain relief scores for up to 8 hours."( Relief of dental surgery pain: a controlled 12-hour comparison of etodolac, aspirin, and placebo.
Bergman, SA; Nelson, SL,
)
0.61
"The effects of age and chronic dosing on the pharmacokinetics of the anti-inflammatory drug etodolac were evaluated in healthy young subjects, healthy elderly subjects, and elderly patients with osteoarthritis."( Etodolac kinetics in the elderly.
Garg, D; Hicks, D; Kraml, M; Sanda, M; Scatina, J; Weidler, D, 1986
)
1.93
" However, the baseline control collections after chronic dosing did not differ from the no-drug control periods."( Effects of nonsteroidal antiinflammatory drugs on renal function in patients with renal insufficiency and in cirrhotics.
Anderson, SA; Brater, DC; Brown-Cartwright, D; Toto, RD, 1986
)
0.27
" A significant positive dose-response relationship was obtained for the three doses of etodolac."( Comparison of etodolac, aspirin and placebo for pain after oral surgery.
Frank, JE; Gaston, GW; Mallow, RD,
)
0.71
"The effect of 7 consecutive days dosing with anti-inflammatory drugs on rat gastric mucosal PGE2 and 6-keto-PGF1 alpha concentrations were studied."( A subchronic study of the effect of etodolac on the gastric mucosal prostaglandin levels in the rat.
Cohen, R; Gilliar, J; Lee, DK; Mulder, B; Smith, T, 1986
)
0.55
" The effects of dosage regimen and/or repetitive dosing on bioavailability were also determined."( Bioavailability studies with etodolac in dogs and man.
Cosyns, L; Dvornik, D; Hicks, DR; Kraml, M; Mullane, JF; Simon, J,
)
0.42
" Therefore, etodolac can generally be given without the need for dosage modifications in special populations such as uncompromised elderly patients, those with moderate renal impairment, and patients with stable hepatic disease."( Pharmacokinetic profile of etodolac in special populations.
Benet, LZ, 1994
)
0.96
"To determine the effects of nabumetone, compared with tiaprofenic acid and etodolac, on anti-inflammatory efficacy and gastrointestinal irritancy in the rat when dosed orally for one month at a high anti-inflammatory dose."( Nabumetone, an effective anti-inflammatory agent, lacks gastrointestinal irritancy in the rat when dosed orally for one month: comparison with tiaprofenic acid and etodolac.
Blower, PR; Gentry, C; Melarange, R; Spangler, R; Toseland, CD, 1994
)
0.71
" Fluctuation ratios upon multiple dosing are comparable for equal total daily doses of etodolac SR and twice-daily doses of the CR formulation."( Pharmacokinetics of sustained-release etodolac.
Benet, LZ, 1993
)
0.78
" In conclusion, acute and chronic dosing of nabumetone at doses up to five times the ID25 did not cause GI damage in rats."( Gastrointestinal damage demonstrated with nabumetone or etodolac in preclinical studies.
Spangler, RS, 1993
)
0.53
" The levels obtained in plasma when the same dose of etodolac is administered orally (tablets, dosage form A) and rectally (suppositories, dosage form B) were compared."( Bioavailability and bioequivalence of two formulations of etodolac (tablets and suppositories).
Cadorniga, R; Fábregas, JL; Gutiérrez, JA; Herrero, R; Iglesias, JM; Martinez-Tobed, A; Molina-Martinez, IT, 1993
)
0.78
" Concurrent disease modifying antirheumatic drugs were not permitted; established low dosage corticosteroid therapy could be continued."( Double blind evaluation of the long-term effects of etodolac versus ibuprofen in patients with rheumatoid arthritis.
Neustadt, DH, 1997
)
0.55
" Etodolac was as effective as naproxen, and the 2 dosage schedules of etodolac were comparable."( Etodolac (Lodine) in the treatment of osteoarthritis: recent studies.
Constantine, G; Schnitzer, TJ, 1997
)
2.65
" IB showed a dose-response relationship which appeared to plateau at doses of 50 and 100 mg/kg."( Effects of the combined oral administration of NSAIDs and dextromethorphan on behavioral symptoms indicative of arthritic pain in rats.
Caruso, FS; Frenk, H; Lu, J; Mao, J; Mayer, DJ; Price, DD, 1996
)
0.29
"Some adaptation occurred in over 90% of subjects after 4 weeks dosing with an NSAID, but adaptation was less frequent in older subjects and in smokers."( The influence of age, gender, Helicobacter pylori and smoking on gastric mucosal adaptation to non-steroidal anti-inflammatory drugs.
Campbell, F; Lipscomb, GR; Rees, WD, 1997
)
0.3
" Using a catheter placed through the auxiliary port of a flexible fiberoptic endoscope, liquid dosage formulations were consistently delivered to the canine stomach, duodenum, ileum, and colon."( Site-specific drug delivery in the dog using flexible fiberoptic endoscopy.
Enever, RP; Heit, MC; Smith, DF, 1998
)
0.3
" Improvement in force transmission was dosage dependent for the primary outcome measurement (vertical impulse)."( Efficacy of etodolac for the treatment of osteoarthritis of the hip joints in dogs.
Budsberg, SC; Claxton, R; DeCamp, CE; Johnston, SA; Schwarz, PD, 1999
)
0.68
" A single 1200 mg dose of etodolac ER given once daily was shown to provide substantial efficacy for 13 hours after dose, modest effect through 24 hours, and a more sustained duration of action than the IR dosage form."( Pharmacokinetic and pharmacodynamic action of etodolac in patients after oral surgery.
Appel, A; Boni, J; Cooper, S; Korth-Bradley, J; McGoldrick, K, 1999
)
0.86
" Applicability of the proposed methods was examined by analysing dosage forms of the investigated drugs."( Spectrophotometric and spectrofluorimetric determination of etodolac and aceclofenac.
El Kousy, NM, 1999
)
0.55
" As a result, drugs that have little or no COX-1 activity across their therapeutic dosage range have been developed."( COX-2 selective nonsteroidal anti-Inflammatory drugs: do they really offer any advantages?
Hawkey, CJ; Jackson, LM, 2000
)
0.31
" The following medications were randomly given to the patients who declared pain in the sixth hour after the operation: naproxen sodium, meloxicam, rofecoxib, paracetamol, dipyrone, and etodolac in proper dosage to form groups of 20 for each medication."( [Postoperative pain management in clinics of otolaryngology].
Cağici, CA; Calişkan, EE; Erkan, AN; Gencay, S; Ozlüoğlu, LN; Sener, M; Yavuz, H; Yilmaz, I; Yilmazer, C, 2006
)
0.52
" Adverse events were generally mild and self-limiting, although in an apparent dose-response relationship, grade 2 and 3 gastrointestinal toxicities and grade 3 skin toxicities were reported with the highest dose regimens (1,800 and 2,400 mg BID)."( Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia.
Engert, A; Jensen, M; Kimby, E; Knauf, W; Oliff, IA; Osterborg, A; Poynton, C; Rummel, MJ; Weissinger, F, 2008
)
0.6
" These results suggested that in situ gelling liquid suppository with etodolac and mucoadhesive polymer was a physically safe, convenient, and effective rectal dosage form for etodolac."( In vitro and in vivo characteristics of a thermogelling rectal delivery system of etodolac.
Barakat, NS, 2009
)
0.81
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
non-steroidal anti-inflammatory drugAn anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins.
cyclooxygenase 2 inhibitorA cyclooxygenase inhibitor that interferes with the action of cyclooxygenase 2.
non-narcotic analgesicA drug that has principally analgesic, antipyretic and anti-inflammatory actions. Non-narcotic analgesics do not bind to opioid receptors.
antipyreticA drug that prevents or reduces fever by lowering the body temperature from a raised state. An antipyretic will not affect the normal body temperature if one does not have fever. Antipyretics cause the hypothalamus to override an interleukin-induced increase in temperature. The body will then work to lower the temperature and the result is a reduction in fever.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
monocarboxylic acidAn oxoacid containing a single carboxy group.
organic heterotricyclic compoundAn organic tricyclic compound in which at least one of the rings of the tricyclic skeleton contains one or more heteroatoms.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
Etodolac Action Pathway2967
Citrate Cycle1930

Protein Targets (50)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency13.45910.007215.758889.3584AID588342
acetylcholinesteraseHomo sapiens (human)Potency70.80620.002541.796015,848.9004AID1347395
thioredoxin reductaseRattus norvegicus (Norway rat)Potency1.58490.100020.879379.4328AID588453
15-lipoxygenase, partialHomo sapiens (human)Potency15.84890.012610.691788.5700AID887
USP1 protein, partialHomo sapiens (human)Potency70.79460.031637.5844354.8130AID743255
NFKB1 protein, partialHomo sapiens (human)Potency25.11890.02827.055915.8489AID895; AID928
AR proteinHomo sapiens (human)Potency56.60350.000221.22318,912.5098AID743035; AID743063
thioredoxin glutathione reductaseSchistosoma mansoniPotency56.23410.100022.9075100.0000AID485364
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
EWS/FLI fusion proteinHomo sapiens (human)Potency26.35060.001310.157742.8575AID1259253
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency63.95620.001530.607315,848.9004AID1224821; AID1224841; AID1224842; AID1224848; AID1224849; AID1259403
estrogen nuclear receptor alphaHomo sapiens (human)Potency48.83440.000229.305416,493.5996AID743075
GVesicular stomatitis virusPotency15.09160.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency43.64860.00108.379861.1304AID1645840
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.02240.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.22390.540617.639296.1227AID2364; AID2528
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency84.921423.934123.934123.9341AID1967
atrial natriuretic peptide receptor 1 precursorHomo sapiens (human)Potency0.15100.134610.395030.1313AID1347049
chromobox protein homolog 1Homo sapiens (human)Potency22.38720.006026.168889.1251AID488953
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency10.32250.00419.984825.9290AID504444
flap endonuclease 1Homo sapiens (human)Potency3.35870.133725.412989.1251AID588795
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency62.95770.000627.21521,122.0200AID743202; AID743219
gemininHomo sapiens (human)Potency0.63100.004611.374133.4983AID624297
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency3.16230.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Interferon betaHomo sapiens (human)Potency15.09160.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency15.09160.01238.964839.8107AID1645842
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency15.09160.01238.964839.8107AID1645842
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
cytochrome P450 2C9, partialHomo sapiens (human)Potency15.09160.01238.964839.8107AID1645842
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency0.80310.060110.745337.9330AID485367; AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 6Rattus norvegicus (Norway rat)Ki100.00001.60005.744010.0000AID598875
Dihydrofolate reductaseHomo sapiens (human)Ki1,800.00000.00000.37564.9000AID1660990
Prostaglandin G/H synthase 1Homo sapiens (human)IC50 (µMol)2.64900.00021.557410.0000AID625243
Prostaglandin G/H synthase 2Homo sapiens (human)IC50 (µMol)0.56100.00010.995010.0000AID625244
Solute carrier family 22 member 6Homo sapiens (human)IC50 (µMol)50.00000.27004.53069.9000AID681160
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (127)

Processvia Protein(s)Taxonomy
tetrahydrobiopterin biosynthetic processDihydrofolate reductaseHomo sapiens (human)
one-carbon metabolic processDihydrofolate reductaseHomo sapiens (human)
negative regulation of translationDihydrofolate reductaseHomo sapiens (human)
axon regenerationDihydrofolate reductaseHomo sapiens (human)
response to methotrexateDihydrofolate reductaseHomo sapiens (human)
dihydrofolate metabolic processDihydrofolate reductaseHomo sapiens (human)
tetrahydrofolate metabolic processDihydrofolate reductaseHomo sapiens (human)
tetrahydrofolate biosynthetic processDihydrofolate reductaseHomo sapiens (human)
folic acid metabolic processDihydrofolate reductaseHomo sapiens (human)
positive regulation of nitric-oxide synthase activityDihydrofolate reductaseHomo sapiens (human)
regulation of removal of superoxide radicalsDihydrofolate reductaseHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 1Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 1Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 1Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 1Homo sapiens (human)
regulation of cell population proliferationProstaglandin G/H synthase 1Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 1Homo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 2Homo sapiens (human)
embryo implantationProstaglandin G/H synthase 2Homo sapiens (human)
learningProstaglandin G/H synthase 2Homo sapiens (human)
memoryProstaglandin G/H synthase 2Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell population proliferationProstaglandin G/H synthase 2Homo sapiens (human)
response to xenobiotic stimulusProstaglandin G/H synthase 2Homo sapiens (human)
response to nematodeProstaglandin G/H synthase 2Homo sapiens (human)
response to fructoseProstaglandin G/H synthase 2Homo sapiens (human)
response to manganese ionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 2Homo sapiens (human)
bone mineralizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fever generationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic plasticityProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergicProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin secretionProstaglandin G/H synthase 2Homo sapiens (human)
response to estradiolProstaglandin G/H synthase 2Homo sapiens (human)
response to lipopolysaccharideProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationProstaglandin G/H synthase 2Homo sapiens (human)
response to vitamin DProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to heatProstaglandin G/H synthase 2Homo sapiens (human)
response to tumor necrosis factorProstaglandin G/H synthase 2Homo sapiens (human)
maintenance of blood-brain barrierProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of protein import into nucleusProstaglandin G/H synthase 2Homo sapiens (human)
hair cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of apoptotic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of nitric oxide biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vasoconstrictionProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
decidualizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle cell proliferationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of inflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
response to glucocorticoidProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of calcium ion transportProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicProstaglandin G/H synthase 2Homo sapiens (human)
response to fatty acidProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to mechanical stimulusProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to lead ionProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to ATPProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to hypoxiaProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to non-ionic osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to fluid shear stressProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of transforming growth factor beta productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fibroblast growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of platelet-derived growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of neuroinflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to homocysteineProstaglandin G/H synthase 2Homo sapiens (human)
response to angiotensinProstaglandin G/H synthase 2Homo sapiens (human)
monoatomic anion transportSolute carrier family 22 member 6Homo sapiens (human)
response to organic cyclic compoundSolute carrier family 22 member 6Homo sapiens (human)
inorganic anion transportSolute carrier family 22 member 6Homo sapiens (human)
organic anion transportSolute carrier family 22 member 6Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 6Homo sapiens (human)
alpha-ketoglutarate transportSolute carrier family 22 member 6Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 6Homo sapiens (human)
sodium-independent organic anion transportSolute carrier family 22 member 6Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 6Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 6Homo sapiens (human)
renal tubular secretionSolute carrier family 22 member 6Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (42)

Processvia Protein(s)Taxonomy
mRNA regulatory element binding translation repressor activityDihydrofolate reductaseHomo sapiens (human)
mRNA bindingDihydrofolate reductaseHomo sapiens (human)
dihydrofolate reductase activityDihydrofolate reductaseHomo sapiens (human)
folic acid bindingDihydrofolate reductaseHomo sapiens (human)
NADPH bindingDihydrofolate reductaseHomo sapiens (human)
sequence-specific mRNA bindingDihydrofolate reductaseHomo sapiens (human)
NADP bindingDihydrofolate reductaseHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peroxidase activityProstaglandin G/H synthase 1Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 1Homo sapiens (human)
protein bindingProstaglandin G/H synthase 1Homo sapiens (human)
heme bindingProstaglandin G/H synthase 1Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 1Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 1Homo sapiens (human)
peroxidase activityProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 2Homo sapiens (human)
protein bindingProstaglandin G/H synthase 2Homo sapiens (human)
enzyme bindingProstaglandin G/H synthase 2Homo sapiens (human)
heme bindingProstaglandin G/H synthase 2Homo sapiens (human)
protein homodimerization activityProstaglandin G/H synthase 2Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 2Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 2Homo sapiens (human)
solute:inorganic anion antiporter activitySolute carrier family 22 member 6Homo sapiens (human)
protein bindingSolute carrier family 22 member 6Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
alpha-ketoglutarate transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
antiporter activitySolute carrier family 22 member 6Homo sapiens (human)
transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
chloride ion bindingSolute carrier family 22 member 6Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 6Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (34)

Processvia Protein(s)Taxonomy
mitochondrionDihydrofolate reductaseHomo sapiens (human)
cytosolDihydrofolate reductaseHomo sapiens (human)
mitochondrionDihydrofolate reductaseHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
photoreceptor outer segmentProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 1Homo sapiens (human)
Golgi apparatusProstaglandin G/H synthase 1Homo sapiens (human)
intracellular membrane-bounded organelleProstaglandin G/H synthase 1Homo sapiens (human)
extracellular exosomeProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 1Homo sapiens (human)
nuclear inner membraneProstaglandin G/H synthase 2Homo sapiens (human)
nuclear outer membraneProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulumProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum lumenProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 2Homo sapiens (human)
caveolaProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
protein-containing complexProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
caveolaSolute carrier family 22 member 6Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 6Homo sapiens (human)
protein-containing complexSolute carrier family 22 member 6Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (195)

Assay IDTitleYearJournalArticle
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1583684Antiviral activity against MERS-CoV infected in African green monkey Vero E6 cells incubated for 48 hrs by neutral red uptake assay2020Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6
Structure-Based Stabilization of Non-native Protein-Protein Interactions of Coronavirus Nucleocapsid Proteins in Antiviral Drug Design.
AID1053260Antagonist activity at human recombinant dopamine D2 long receptor expressed in CHOK1 cells coexpressing mitochondrial apoaequorin assessed as inhibition of agonist-induced effect at 50 uM after 15 mins by luminometric analysis relative to haloperidol2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1053266Agonist activity at human recombinant dopamine D1 receptor expressed in CHOK1 cells assessed as stimulation of cAMP accumulation at 100 uM after 30 mins by HTRF assay relative to SKF812972013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID1053264Antagonist activity at human recombinant dopamine D1 receptor expressed in CHOK1 cells assessed as inhibition of agonist-induced cAMP accumulation at 100 uM preincubated for 10 mins prior to agonist addition measured after 30 mins by HTRF assay relative t2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID28681Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID176727Dose causing 50% inhibition of edema by carrageenan paw edema assay1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Synthesis and analgesic activity of pemedolac (cis-1-ethyl-1,3,4,9-tetrahydro-4-(phenylmethyl)pyrano[3,4-b]ind ole-1- acetic acid).
AID1145137Antiinflammatory activity in po dosed rat assessed as inhibition of carrageenin-induced paw edema1976Journal of medicinal chemistry, Mar, Volume: 19, Issue:3
Etodolic acid and related compounds. Chemistry and antiinflammatory actions of some potent di- and trisubstituted 1, 3, 4, 9-tetrahydropyrano[3, 4-b]indole-1-acetic acids.
AID598875Inhibition of rat Oat1 expressed in pig LLC-PK11 cells2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
Elucidation of common pharmacophores from analysis of targeted metabolites transported by the multispecific drug transporter-Organic anion transporter1 (Oat1).
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1851392Inhibition of eEF2K in human MDA-MB-231 cells assessed as decrease in phosphorylation of eEF2 at Thr56 residue at 2.5 to 20 uM incubated for 2 hrs by western blot analysis2022RSC medicinal chemistry, Jul-20, Volume: 13, Issue:7
Novel etodolac derivatives as eukaryotic elongation factor 2 kinase (eEF2K) inhibitors for targeted cancer therapy.
AID1220241Intrinsic clearance in human intestinal microsomes assessed CYP450-mediated glucuronidation clearance2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID176730Dose causing an analgesic effect in 50% of rats (Randall-Selitto assay)1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Synthesis and analgesic activity of pemedolac (cis-1-ethyl-1,3,4,9-tetrahydro-4-(phenylmethyl)pyrano[3,4-b]ind ole-1- acetic acid).
AID373867Hepatic clearance in human hepatocytes in absence of fetal calf serum2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
First-principle, structure-based prediction of hepatic metabolic clearance values in human.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1583682Cytotoxicity in African green monkey Vero E6 cells incubated for 48 hrs by neutral red uptake assay2020Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6
Structure-Based Stabilization of Non-native Protein-Protein Interactions of Coronavirus Nucleocapsid Proteins in Antiviral Drug Design.
AID189995Dose at which 50% of the rats had a positive gastrointestinal irritation / ulceration on a quantal all-or-none basis1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Synthesis and analgesic activity of pemedolac (cis-1-ethyl-1,3,4,9-tetrahydro-4-(phenylmethyl)pyrano[3,4-b]ind ole-1- acetic acid).
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID183056Inhibition against adjuvant-induced paw edema at a dose of 25 mg/kg in male Sprague-Dawley rats.1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Structure-activity relationships among analogues of pemedolac, cis-1-ethyl-1,3,4,9-tetrahydro-4-(phenylmethyl)pyrano[3,4-b]indo le-1-a cetic acid, a potent analgesic agent.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1150596Chronic antiinflammatory activity against adjuvant-induced arthritis in po dosed rat assessed as decrease in volume of paw administered for 9 days starting 14 days after adjuvant injection and continued until day 22 by therapeutic test1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Cycloalkanoindoles. 1. Syntheses and antiinflammatory actions of some acidic tetrahydrocarbazoles, cyclopentindoles, and cycloheptindoles.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID363515Selectivity ratio of IC50 for human COX1 to IC50 for human COX2 by whole blood assay2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
Synthesis, in vitro, and in vivo biological evaluation and molecular docking simulations of chiral alcohol and ether derivatives of the 1,5-diarylpyrrole scaffold as novel anti-inflammatory and analgesic agents.
AID475147Inhibition of DMBA-induced/TPA-promoted skin carcinogenesis in ICR mouse assessed as reduction in tumor burden at 0.0025% topically applied qd treated one week before DMBA-TPA challenge after 20 weeks relative to control2010Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
Chemopreventive activities of etodolac and oxyphenbutazone against mouse skin carcinogenesis.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1150602Ratio of ED50 for ulcerogenicity in 24-hrs starved Charles-River rat to ED50 for chronic antiinflammatory activity against adjuvant-induced arthritis in rat1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Cycloalkanoindoles. 1. Syntheses and antiinflammatory actions of some acidic tetrahydrocarbazoles, cyclopentindoles, and cycloheptindoles.
AID243647In vitro inhibitory activity against ovine cyclooxygenase-1 (COX-1) at 200 uM; Inactive2004Journal of medicinal chemistry, Sep-23, Volume: 47, Issue:20
Novel cyclooxygenase-1 inhibitors discovered using affinity fingerprints.
AID1220248Activity of human UGT1A9 expressed in insect cells assessed as reduction in compound level after 30 mins2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
AID1150601Ulcerogenicity in po dosed 24-hrs starved Charles-River rat assessed as lesions on stomach administered as single dose measured after 18 hrs1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Cycloalkanoindoles. 1. Syntheses and antiinflammatory actions of some acidic tetrahydrocarbazoles, cyclopentindoles, and cycloheptindoles.
AID1660990Inhibition of human DHFR in presence of DHF and NADPH by UV-vis spectrometry by Lineweaver-Burk plot analysis2020Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15
The Structural Basis for Nonsteroidal Anti-Inflammatory Drug Inhibition of Human Dihydrofolate Reductase.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID27167Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID24425Partition coefficient (logP)1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Structure-activity relationships among analogues of pemedolac, cis-1-ethyl-1,3,4,9-tetrahydro-4-(phenylmethyl)pyrano[3,4-b]indo le-1-a cetic acid, a potent analgesic agent.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1220255Apparent permeability by PAMPA method2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
AID5985261-Octanol-water distribution coefficient, log D of the compound at pH 7.4 by shake-flask method2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.
AID475151Toxicity in ICR mouse at 0.0025%, po2010Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
Chemopreventive activities of etodolac and oxyphenbutazone against mouse skin carcinogenesis.
AID52139Inhibitory activity against prostaglandin biosynthesis in stimulated chondrocyte cell culture1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Structure-activity relationships among analogues of pemedolac, cis-1-ethyl-1,3,4,9-tetrahydro-4-(phenylmethyl)pyrano[3,4-b]indo le-1-a cetic acid, a potent analgesic agent.
AID1220260Oral bioavailability in human2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1053262Agonist activity at human recombinant dopamine D2 long receptor expressed in CHOK1 cells coexpressing mitochondrial apoaequorin at 100 uM by luminometric analysis relative to quinpirol2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID160557In vitro inhibition of prostaglandin E2 production in cultured chondrocytes1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Synthesis and biological evaluation of 4,6-diethyl-1,3,4,5-tetrahydropyrano[4,3-b]indole-4-acetic acid, an isomer of etodolac.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID257049Inhibition of recombinant human AKR1C32005Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
Nonsteroidal anti-inflammatory drugs and their analogues as inhibitors of aldo-keto reductase AKR1C3: new lead compounds for the development of anticancer agents.
AID408486Inhibition of recombinant Curvularia lunata trihydroxynaphthalene reductase2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Towards the first inhibitors of trihydroxynaphthalene reductase from Curvularia lunata: synthesis of artificial substrate, homology modelling and initial screening.
AID1220256Total clearance in human2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
AID363513Inhibition of COX1 in human whole blood assessed as inhibition of LPS-stimulated PGE2 production by radioimmunoassay2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
Synthesis, in vitro, and in vivo biological evaluation and molecular docking simulations of chiral alcohol and ether derivatives of the 1,5-diarylpyrrole scaffold as novel anti-inflammatory and analgesic agents.
AID1636440Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1636356Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID235829Ratio of acute ulcerogenesis UD50/Randall-Selitto ED501988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Synthesis and analgesic activity of pemedolac (cis-1-ethyl-1,3,4,9-tetrahydro-4-(phenylmethyl)pyrano[3,4-b]ind ole-1- acetic acid).
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1220237Unbound fraction during UGT-mediated glucuronidation in human intestinal microsomes2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
AID183690Evaluated for the inhibition of adjuvant-induced hind paw edema in rats at 25 mg/kg dose1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Etodolac, a novel antiinflammatory agent. The syntheses and biological evaluation of its metabolites.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID681160TP_TRANSPORTER: inhibition of Adefovir uptake in OAT1-expressing CHO cells2000The Journal of pharmacology and experimental therapeutics, Oct, Volume: 295, Issue:1
Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1.
AID1576544Antiinflammatory activity against TPA-induced ear edema in BALB/c mouse assessed as effect on weight of ear punches at 100 mg/kg, po administered 6 mins prior to TPA challenge and treated twice in 4 hrs and measured after 6 hrs post administration (Rvb = 2019MedChemComm, Oct-01, Volume: 10, Issue:10
Synergistic effect of tolfenamic acid and glycyrrhizic acid on TPA-induced skin inflammation in mice.
AID1220238Intrinsic clearance in human intestinal microsomes assessed UGT-mediated glucuronidation clearance2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
AID1220258Renal clearance in human2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1220240Unbound fraction during CYP4500-mediated metabolism in human intestinal microsomes2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
AID1583680Binding affinity to N-terminal domain of MERS-CoV nucleocapsid protein assessed as interaction with W43 pocket at 10 uM incubated for 1 hr by fluorescence spectral analysis2020Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6
Structure-Based Stabilization of Non-native Protein-Protein Interactions of Coronavirus Nucleocapsid Proteins in Antiviral Drug Design.
AID363514Inhibition of COX2 in human whole blood assessed as inhibition of TXB2 production by radioimmunoassay2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
Synthesis, in vitro, and in vivo biological evaluation and molecular docking simulations of chiral alcohol and ether derivatives of the 1,5-diarylpyrrole scaffold as novel anti-inflammatory and analgesic agents.
AID231760Ratio of carrageenan paw edema ED50/Randall-Sellitto ED501988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Synthesis and analgesic activity of pemedolac (cis-1-ethyl-1,3,4,9-tetrahydro-4-(phenylmethyl)pyrano[3,4-b]ind ole-1- acetic acid).
AID1220242Unbound intrinsic clearance in human intestinal microsomes assessed CYP450-mediated glucuronidation clearance2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
AID43581Inhibition of beta-lactamase at 100 uM2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID1220259Oral absorption in human2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1145138Gastrointestinal toxicity in 8 hrs starved po dosed Charles River rat assessed as ulcerogenic effect after 18 hrs1976Journal of medicinal chemistry, Mar, Volume: 19, Issue:3
Etodolic acid and related compounds. Chemistry and antiinflammatory actions of some potent di- and trisubstituted 1, 3, 4, 9-tetrahydropyrano[3, 4-b]indole-1-acetic acids.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1636357Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID106806Inhibition of malate dehydrogenase (MDH) at 400 uM2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID52790Inhibition of chymotrypsin at 250 uM2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID178650Antiinflammatory activity of the perorally administered compound assessed in adjuvant arthritis assay in rat1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Synthesis and biological evaluation of 4,6-diethyl-1,3,4,5-tetrahydropyrano[4,3-b]indole-4-acetic acid, an isomer of etodolac.
AID1145133Antiinflammatory activity in rat assessed as inhibition of adjuvant-induced arthritis administered for 9 days into foot pad 14 days after adjuvant challenge measured on day 22 by mercury displacement analysis1976Journal of medicinal chemistry, Mar, Volume: 19, Issue:3
Etodolic acid and related compounds. Chemistry and antiinflammatory actions of some potent di- and trisubstituted 1, 3, 4, 9-tetrahydropyrano[3, 4-b]indole-1-acetic acids.
AID5985271-Octanol-sodium citrate buffer distribution coefficient, log D of the compound at pH 5.5 by shake-flask method2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.
AID1220236Oral clearance in human2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
AID625276FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID1145139Therapeutic index, ratio of UD50 for 8 hrs starved po dosed Charles River rat to ED50 for rat assessed as inhibition of adjuvant-induced arthritis1976Journal of medicinal chemistry, Mar, Volume: 19, Issue:3
Etodolic acid and related compounds. Chemistry and antiinflammatory actions of some potent di- and trisubstituted 1, 3, 4, 9-tetrahydropyrano[3, 4-b]indole-1-acetic acids.
AID130878Inhibition against writhing induced by Phenylbenzoquinone in male swiss albino mice1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Structure-activity relationships among analogues of pemedolac, cis-1-ethyl-1,3,4,9-tetrahydro-4-(phenylmethyl)pyrano[3,4-b]indo le-1-a cetic acid, a potent analgesic agent.
AID52141Evaluated in vitro for its ability to inhibit prostaglandin E2 production in cultured chondrocyte cells at 25 mg/kg dose1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Etodolac, a novel antiinflammatory agent. The syntheses and biological evaluation of its metabolites.
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID598525Lipophilicity, log P of the compound2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID204102Effect of compound (400 uM) on biosynthesis of prostaglandins from tritiated arachidonic acid was evaluated in vitro; NE = No effect at the given concentration1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Resolution of etodolac and antiinflammatory and prostaglandin synthetase inhibiting properties of the enantiomers.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID225499Dose causing 50% inhibition of writhing in mouse (PBQ writhing test)1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Synthesis and analgesic activity of pemedolac (cis-1-ethyl-1,3,4,9-tetrahydro-4-(phenylmethyl)pyrano[3,4-b]ind ole-1- acetic acid).
AID1150600Acute antiinflammatory activity in po dosed rat assessed as inhibition of carrageenan-induced paw edema1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Cycloalkanoindoles. 1. Syntheses and antiinflammatory actions of some acidic tetrahydrocarbazoles, cyclopentindoles, and cycloheptindoles.
AID677462Dissociation constant, pKa of the compound2012European journal of medicinal chemistry, Jul, Volume: 53Self-organizing molecular field analysis of NSAIDs: assessment of pharmacokinetic and physicochemical properties using 3D-QSPkR approach.
AID599064Plasma protein binding in human2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1220239Unbound intrinsic clearance in human intestinal microsomes assessed UGT-mediated glucuronidation clearance2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1220257Ratio of drug level in blood to plasma in human2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1345206Human COX-2 (Cyclooxygenase)2001The Journal of pharmacy and pharmacology, Dec, Volume: 53, Issue:12
Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: investigation using human peripheral monocytes.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (510)

TimeframeStudies, This Drug (%)All Drugs %
pre-199074 (14.51)18.7374
1990's114 (22.35)18.2507
2000's171 (33.53)29.6817
2010's120 (23.53)24.3611
2020's31 (6.08)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 90.67

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index90.67 (24.57)
Research Supply Index6.52 (2.92)
Research Growth Index4.65 (4.65)
Search Engine Demand Index165.77 (26.88)
Search Engine Supply Index2.02 (0.95)

This Compound (90.67)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials125 (22.73%)5.53%
Reviews49 (8.91%)6.00%
Case Studies34 (6.18%)4.05%
Observational0 (0.00%)0.25%
Other342 (62.18%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (25)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase 2 Study of VT-122 in Combination With Sorafenib Compared to Sorafenib With Placebo in Patients With Hepatocellular Carcinoma and Systemic Inflammation at Risk for Cachexia [NCT01265576]Phase 220 participants (Actual)Interventional2010-12-31Active, not recruiting
Perioperative Use of a β-adrenergic Blocker, Propranolol, and a COX2 Inhibitor, Etodolac, in Patients Undergoing Resection With Curative Intent for Primary Colon and Rectal Cancer: Effect on Tumor Recurrence and Survival [NCT03919461]Phase 2200 participants (Anticipated)Interventional2019-02-28Recruiting
Perioperative Use of a Beta-adrenergic Blocker and a COX-2 Inhibitor in Patients Undergoing Surgery With Primary Pancreatic Cancer: Intervention Aiming to Reduce Pro-metastatic Processes [NCT03838029]Phase 2210 participants (Anticipated)Interventional2019-11-20Recruiting
Safety and Efficacy of Meloxicam (MOBIC) Compared to Other NSAIDs in Approved Therapeutic Dosages and Routes of Administration in an Observational Cohort Study of Patients With Rheumatoid Arthritis, Osteoarthritis, Lumbago, Scapulohumeral Periarthritis, N [NCT02180516]9,984 participants (Actual)Observational2001-10-31Completed
A Phase III Study of YM177 (Postoperative Pain) -- An Etodolac- and Placebo-controlled, Multicenter, Double-blind, Group Comparison Study to Verify the Efficacy of YM177 (Celecoxib) in Postoperative Pain Patients -- [NCT01118572]Phase 3616 participants (Actual)Interventional2010-02-28Completed
A Randomized, Multi-Center, Double-Blind, Factorial, Comparator and Placebo-Controlled Phase III Trial to Evaluate the Efficacy, Tolerability and Safety of MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Ankle Sprains [NCT01198834]Phase 3600 participants (Actual)Interventional2010-09-30Completed
A Randomized, Placebo Controlled, Multicenter Phase 2 Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer [NCT01857817]Phase 235 participants (Actual)Interventional2013-06-30Terminated(stopped due to Low patient recruitment)
Evaluation of the Effects of Treatments Applied to Patients With Facial Myalgia on Quality of Life and Occlusion Parameters [NCT05261971]60 participants (Actual)Interventional2018-12-01Completed
Perioperative β-adrenergic Blocker and a COX2 Inhibitor in Patients Undergoing Resection for Primary Colon and Rectal Cancer: Effect on Tumor Recurrence and Postoperative Immune Perturbations. A Multicenter Randomized Prospective Trial. [NCT00888797]Phase 3400 participants (Anticipated)Interventional2010-01-31Recruiting
Preemptive Use of Etodolac on Tooth Sensitivity Caused by In-office Bleaching: a Randomized, Triple-blind, Controlled Clinical Trial [NCT02881619]Phase 450 participants (Actual)Interventional2014-11-30Completed
Comparison of Lornoxicam and Etodolac on Edema, Trismus and Pain After Third Molar Surgery [NCT05679453]Phase 420 participants (Actual)Interventional2022-07-20Completed
A Randomized, Multi-Center, Phase II Study to Investigate the Safety and Efficacy of SDX-101 (R-etodolac) in Combination With Chlorambucil, and That of Chlorambucil Alone, in Patients With Chronic Lymphocytic Leukemia (CLL) [NCT00151736]Phase 288 participants (Actual)Interventional2004-09-30Terminated
Phase III Randomized, Unicentric, Double-masked, Parallel Trial for the Efficacy and Tolerability of the Fixed Dose Combination of Etodolac 400 mg and Cyclobenzaprine 10 mg Versus the Isolated Active Substances (Flancox® 400 mg And Miosan® 10 mg) in Posto [NCT03127592]Phase 3140 participants (Actual)Interventional2020-10-05Terminated(stopped due to recruitment difficulty)
A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Phase III Trial to Evaluate the Efficacy, Tolerability and Safety of Etoreat®(Etodolac-Lidocaine Topical Patch) in the Treatment of Acute Low Back Pain [NCT01968005]Phase 3232 participants (Actual)Interventional2013-11-30Completed
A Randomized, Double-blind, Multiple-dose, Placebo-controlled Study to Evaluate the Efficacy and Safety of Etodolac-lidocaine Patch Applied Once Daily in Subjects Experiencing Acute Delayed Onset Muscle Soreness [NCT02695381]Phase 3100 participants (Actual)Interventional2016-03-31Completed
An Open Label, Balanced, Randomized, Single-dose, Two-treatment, Two-sequence, Two-period, Crossover, Oral Bioequivalence Study of Etodolac Capsules USP 300 mg of Ipca Laboratories Limited, India and Etodolac Capsules USP 300mg of Taro Pharmaceutical Indu [NCT01749228]Phase 136 participants (Actual)Interventional2012-10-31Completed
Perioperative Administration of COX 2 Inhibitors and Beta Blockers in Women Undergoing Breast Cancer Surgery: an Intervention to Decrease Immune Suppression, Metastatic Potential and Cancer Recurrence [NCT00502684]32 participants (Anticipated)Interventional2014-06-30Recruiting
An Open Label, Balanced, Randomized, Single-dose, Two-treatment, Two-sequence, Two-period, Crossover, Oral Bioequivalence Study of Etodolac Extended Release Tablets USP 600mg of Ipca Laboratories Limited, India and Etodolac Extended Release Tablets 600mg [NCT01831687]Phase 136 participants (Actual)Interventional2012-12-31Completed
An Open Label, Multi-Center, Phase II Study to Investigate the Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory Multiple Myeloma (MM) [NCT00293111]Phase 230 participants Interventional2002-02-28Terminated
The Effect on Knee Joint Loads of Instruction in Analgesic Use Compared With NEUROMUSCULAR Exercise in Patients With Knee Osteoarthritis - A Single Blind RCT [NCT01638962]93 participants (Actual)Interventional2012-08-31Completed
An Open Label, Balanced, Randomized, Single-dose, Two-treatment, Two-sequence, Two-period, Crossover, Oral Bioequivalence Study of Etodolac Tablets USP 500mg of Ipca Laboratories Limited, India and Etodolac Tablets USP 500mg of Taro Pharmaceutical Industr [NCT01735370]Phase 136 participants (Actual)Interventional2012-05-31Completed
An Open Label, Balanced, Randomized, Single-dose, Two-treatment, Two-sequence, Two-period, Crossover, Oral Bioequivalence Study of Etodolac Tablets USP 500mg of Ipca Laboratories Limited, India and Etodolac Tablets USP 500mg of Taro Pharmaceutical Industr [NCT01735383]Phase 136 participants (Actual)Interventional2012-05-31Completed
An Open Label, Balanced, Randomized, Single-dose, Two-treatment, Two-sequence, Two-period, Crossover, Oral Bioequivalence Study of Etodolac Capsules USP 300 mg of Ipca Laboratories Limited, India and Etodolac Capsules USP 300mg of Taro Pharmaceutical Indu [NCT01746719]Phase 136 participants (Actual)Interventional2012-10-31Completed
An Open Label, Balanced, Randomized, Single-dose, Two-treatment, Two-sequence, Two-period, Crossover, Oral Bioequivalence Study of Etodolac Extended Release Tablets USP 600mg of Ipca Laboratories Limited, India and Etodolac Extended Release Tablets 600mg [NCT01827865]Phase 136 participants (Actual)Interventional2012-11-30Completed
Perioperative Stress Reduction in Ovarian Cancer (PRESERVE Trial)-A Prospective Randomized Pilot Study [NCT05429970]30 participants (Anticipated)Interventional2022-06-17Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]